Edward Keystone

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

Michael E. Weinblatt, Edward Keystone, Daniel E. Furst et al. · Arthritis & Rheumatism · 2003 · 1.8K citations

Medicine, Pharmacology, Pharmacotherapy +15

A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

Joan M. Bathon, Richard W. Martin, Roy Fleischmann et al. · New England Journal of Medicine · 2000 · 1.8K citations · Full text

Medicine, Immunology, Pharmacology +12

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Stanley Cohen, Paul Emery, Maria Greenwald et al. · Arthritis & Rheumatism · 2006 · 1.6K citations

Medicine, Pharmacology, Pharmacotherapy +16

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial

Edward Keystone, Arthur F. Kavanaugh, John T. Sharp et al. · Arthritis & Rheumatism · 2004 · 1.2K citations

Life Sciences, Immunology, Pharmacotherapy +17

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial

E. William St. Clair, Désirée van der Heijde, Josef S Smolen et al. · Arthritis & Rheumatism · 2004 · 1.2K citations

Medicine, Pharmacology, Pharmacotherapy +12